Jesse's Journey Foundation

Defeat Duchenne. Change Lives.

Sarepta Bolstered by Doctor Letter Urging FDA Approval of DMD Drug

Thirty-six doctors, all experts in Duchenne muscular dystrophy, or DMD, have written a letter to the U.S. Food and Drug Administration urging the agency to approve Sarepta Therapeutics’ (SRPT – Get Report) experimental therapy eteplirsen.

The lobbying effort seeking to bolster support for eteplirsen and Sarepta — and counter previously released FDA criticism of the drug — is ramping up as an advisory committee meeting on April 25 nears. Click here to read more.

News Archive